Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday ...

Mexico's type 2 diabetes crisis, with a prevalence of 16·9%, has made the country a focal point for fiscal policies targeting ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

NBC News and MSNBC medical contributor Dr. Kavita Patel joins ‘Fast Money’ to discuss Novo Nordisk after the company ousted ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Estrogen generated in the brain may play a role in regulating appetite, potentially opening new avenues for treating obesity.

The $7.8 million investment will fund further drug testing and development to advance its drug candidates to clinical trials.

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

Novo Nordisk is moving forward with plans to develop oral obesity drugs through a new partnership, which comes as longtime CEO Lars Fruergaard Jørgensen prepares to step down. The drugmaker launched a ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.